Four main classes of human tumor antigens recognized by T cells: 1- "Cancer-testis" antigens: non-mutated genes reactivated in neoplastic cells, but
|
|
- Bethany Gaines
- 5 years ago
- Views:
Transcription
1 Tumor antigens Andrea Anichini Human Tumors Immunobiology Unit, Dept. of Experimental Oncology and Molecular Medicine Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
2 Timeline of the discovery of the genes encoding tumor-associated antigens Four main classes of human tumor antigens recognized by T cells: 1- "Cancer-testis" antigens: non-mutated genes reactivated in neoplastic cells, but generally silenced in normal cells, with exception of male germ line cells and trophoblasts. 2- Tissue-specific self antigens. 3- Neoantigens resulting from nonsynomymous somatic mutations in neoplastic cells. 4- Normal genes overexpressed in cancer cells
3 A single tumor can express all classes of antigens: Tumor-associated antigens in B-NHL Tumor-associated antigens 1-Tumor-specific idiotype. 2-Shared antigens T cell recognition -Somatically mutated lymphoma Ig regions code for peptides recognized by patients T cells as tumor-specific antigens (Gricks 2001)- -non-mutated, germ-line V region sequences code for peptides recognized as shared antigens by patients T cells (Trojan, 2000). 3-B cell differentiation antigens. CD19 and CD20 encode peptides recognized by patients and healthy donors CD8+CTLs. (Grube 2004). 4-Over-expressed -Apoptosis regulators. Bcl-2 peptide-specific T cells in CLL patients (Andersen 2005) -Proteoglycans. Fibromodulin, overexpressed in CLL compared to normal B cells, encodes for peptides recognized by CTLs (Mayr, 2005)
4 Some antigens expressed by human melanoma Class Antigen peptide sequence HLA Cancer testis MAGE1 EADPTGHSY A1 MAGE3 FLWGPRALV A2 NY-ESO-1 SLLMWITQC A2 Mutated CDK4 ACDPHSGHFV A2 proteins β-catenin SYLDSGIHF A24 Cdc27 FSWAMDLDPKGA DR4 tissue specific antigens Tirosinasi YMDGTMSQV A2 gp100 ITDQVPFSV A2 Melan-A/Mart-1 AAGIGILTV A2 Trp-2 LLGPGRPYR A31
5 processing of a single protein can generate several peptides recognized by CD4+ and CD8+ T cells. HER-2 peptides recognized by T cells. HLA-Class II HLA-Class I (a) (b) (c) (d) (e) A33 A24 A11 A3 A Domain I Domain II Domain III Domain IV TM Tyrosine Kinase Regulatory Region Pertuzumab binding site Herceptin binding site bcr (a),(b),(c),(d),(e): distinct HLA Class II alleles and sometimes promiscuous epitopes
6 One gene, several tumor antigens, and different T and B subsets that recognize them HLA Class II CD4 Treg HLA Class I - CD8 - + HLA Class II CD4 TH B +
7 The same protein expressed in neoplastic cells can be target of B and T cells: immune response to tumors is integrated. B cell response T cell response HLA-peptide Comples TCR T T T
8 Biomarkers of response to anti-ctla-4 Pre-existing antibody response and T/B integrated response to NY-ESO-1 associated with clinical benefit to anti-ctla-4
9 How MHC Class I- peptide complexes are generated
10 MHC Class I vs MHC Class II antigen processing pathwyas
11 How the TCR "sees" the MHC-peptide complex CDR CDR peptide TCR-A TCR-B
12 How the TCR "sees" the MHC-peptide complex CDR3 CDR3 peptide
13 Molecular mechanisms that generate antigens recognized by T cells on tumor cells DNA mrna Protein Peptide Peptide Peptide (epitope o agretope*) (cryptic promoter) Peptide 4 (alternative orf) 5 Peptide (intron retention) 6 Peptide (post-traslational modification) *n.b.epitope: part of the peptide that interacts with the TCR agretope: part of the peptide that interacts with the HLA molecule
14 Protein and peptide surgery New mechanisms generate TAA recognized by T cells... Nature 427:252, Vigneron et al. Science 304:587, 2004 An antigenic peptide produced by peptide splicing in the proteasome R T K A W N R Q L Y P E W bibliografia: Science Science 304:587 Nature 427:252 R T K Q L Y P E W
15 Imagine you are in 1996 and you want to clone a tumor antigen
16 Cloning of tumor antigen genes recognized by patients' antibodies: SEREX approach tumor mrna cdna libraries in expression vectors Bacteria Screening by antibodies from patients' serum serex : serological analysis of recombinant cdna expression libraries
17 Antigen classes recognized by B cells and identified by SEREX 1. Cancer testis (CT) ags Mages NY-ESO-1 HOM-Mel-40/SSX2 CT7 SCP-1 BAGE GAGE NW-BR-3 2. mutated genes p53 LKB/STKII 3. amplified/overexpressed genes eif-4γ Carbonic anhydrase XII HER-2/neu 4.splicing variants 5. differentiation antigens (tissue-specific) Fibulin-1 NY-CO-37/PDZ-45 ING-1 NY-BR-1 Tyrosinase Galectin-4
18 Now you are in 2016 and want to identify new tumor antigens NPR1: Atrial natriuretic peptide receptor 1 KLGDFVA TL A TLHRRLGW T cell Rizvi et al. Mutational landscape determines sensitivity to PD-1 blockade in non small cell lung cancer. Science 348: , 2015
The next steps for effective cancer immunotherapy and viral vaccines. Peter Selby FACP(UK)
The next steps for effective cancer immunotherapy and viral vaccines Peter Selby FACP(UK) Richard Alan Steve Sasha Matt Nav Vile Melcher Griffin Zougman Bentham Vasudev Adel Nick Gemma Liz Samson Hornigold
More informationTumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)
Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of
More informationA listing of human tumor antigens recognized by T cells: March 2004
A listing of human tumor antigens recognized by T cells: March 2004 update Luisa Novellino - Chiara Castelli - Giorgio Parmiani Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Via G.
More informationHuman tumor antigens recognized by T lymphocytes: implications for cancer therapy
Human tumor antigens recognized by T lymphocytes: implications for cancer therapy Rong-Fu Wang and Steven A. Rosenberg Surgery Branch, National Cancer institute, Bethesda, Maryland Abstract: The adoptive
More informationBasic Immunology. Lecture 26 th. Immunity against tumors
Basic Immunology Lecture 26 th Immunity against tumors Neoplastic transformations are genetic alterations. Expression of cell surface antigens both self and non-self - seen by immune system. Ehrlich positive
More informationPEPTIDES AS TUMOR ANTIGENS
REVIEW Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going? Giorgio Parmiani, Chiara Castelli, Piero Dalerba, Roberta Mortarini, Licia Rivoltini, Francesco M. Marincola,
More informationTwo categories of immune response. immune response. infection. (adaptive) Later immune response. immune response
Ivana FELLNEROVÁ E-mail: fellneri@hotmail.com, mob. 732154801 Basic immunogenetic terminology innate and adaptive immunity specificity and polymorphism immunoglobuline gene superfamily immunogenetics MHC
More informationCancer Immunotherapy: Active Immunization Approaches
Cancer Immunotherapy: Active Immunization Approaches Willem W. Overwijk, PhD Department of Melanoma Medical Oncology MD Anderson Cancer Center Houston, TX, USA Disclosures No relevant financial relationships
More informationCancer Vaccines and Cytokines. Elizabeth A. Mittendorf, MD, PhD Assistant Professor Department of Surgical Oncology
Cancer Vaccines and Cytokines Elizabeth A. Mittendorf, MD, PhD Assistant Professor Department of Surgical Oncology Disclosures I serve as the PI on a phase III trial sponsored by Galena BioPharma investigating
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationFrom basic to tumour immunology for oncologists
From basic to tumour immunology for oncologists Andrea Anichini Human Tumors Immunobiology Unit, Dept. of Experimental Oncology and Molecular Medicine Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
More informationCancer Vaccine Collaborative 2002: Opening address
LATEST PAPERS SEARCH for PAPERS Printer-friendly PDF Comment(s) >Text >Contact author Cancer Immunity, Vol. 3 Suppl. 1, p. 1 (6 February 2003) Cancer Vaccine Collaborative 2002: Opening address Lloyd J.
More informationImmunology Lecture 4. Clinical Relevance of the Immune System
Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor
More informationT cell Receptor. Chapter 9. Comparison of TCR αβ T cells
Chapter 9 The αβ TCR is similar in size and structure to an antibody Fab fragment T cell Receptor Kuby Figure 9-3 The αβ T cell receptor - Two chains - α and β - Two domains per chain - constant (C) domain
More informationCancer immunity and immunotherapy. General principles
1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or
More informationNeoantigen Identification using ATLAS Across Multiple Tumor Types Highlights Limitations of Prediction Algorithms
Neoantigen Identification using ATLAS Across Multiple Tumor Types Highlights Limitations of Prediction Algorithms Wendy Broom, Ph.D. Keystone: Translational Systems Immunology, Snowbird February 1st 2018
More informationIntroduction. Introduction. Lymphocyte development (maturation)
Introduction Abbas Chapter 8: Lymphocyte Development and the Rearrangement and Expression of Antigen Receptor Genes Christina Ciaccio, MD Children s Mercy Hospital January 5, 2009 Lymphocyte development
More informationTumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School
Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor
More informationCyclin B1: Abnormal Self /Tumor Antigen. Laura Ann Vella. BA, University of Delaware. Submitted to the Graduate Faculty of
Cyclin B1: Abnormal Self /Tumor Antigen by Laura Ann Vella BA, University of Delaware Submitted to the Graduate Faculty of The School of Medicine in partial fulfillment of the requirements for the degree
More informationMHC class I MHC class II Structure of MHC antigens:
MHC class I MHC class II Structure of MHC antigens: MHC class I antigens consist of a transmembrane heavy chain (α chain) that is non-covalently associated with β2- microglobulin. Membrane proximal domain
More informationTherapeutic Vaccines in Cancer
Therapeutic Vaccines in Cancer Kunle Odunsi, M.D., Ph.D. 1,2 Department of Gynecologic Oncology 1 Center for Immunotherapy 2 Roswell Park Cancer Institute Buffalo, NY Model of immune recognition of human
More informationACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics
ACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics Precision Genomics for Immuno-Oncology Personalis, Inc. ACE ImmunoID When one biomarker doesn t tell the whole
More informationEndogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade
Endogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade Jedd Wolchok Ludwig Center for Cancer Immunotherapy Memorial Sloan-Kettering Cancer Center MEMORIAL SLOAN- KETTERING
More informationStructure and Function of Antigen Recognition Molecules
MICR2209 Structure and Function of Antigen Recognition Molecules Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will examine the major receptors used by cells of the innate and
More informationMHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery
MHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery Your Partner in Drug Discovery and Research MHC Tetramer Background T-Cell Receptors recognize and bind to complexes composed
More informationLeukemia (2007) 21, & 2007 Nature Publishing Group All rights reserved /07 $
REVIEW (2007) 21, 1859 1874 & 2007 Nature Publishing Group All rights reserved 0887-6924/07 $30.00 www.nature.com/leu Department of Immunohematology and Blood Transfusion, Leiden University Medical Center,
More informationMajor Histocompatibility Complex (MHC) and T Cell Receptors
Major Histocompatibility Complex (MHC) and T Cell Receptors Historical Background Genes in the MHC were first identified as being important genes in rejection of transplanted tissues Genes within the MHC
More informationImmune surveillance: The immune system can recognize and destroy nascent malignant cells
Immune surveillance: The immune system can recognize and destroy nascent malignant cells Control Escape APC T C T H B NKT NK Innate Tumor T cells are believed to play a major role in controlling tumor
More informationTumor responses (patients responding/ patients treated)
Table 1. ACT clinical trial tumor responses and toxicities. a Target antigen Cancer(s) Receptor type Tumor responses (patients responding/ patients treated) Immune-mediated toxicities (patients experiencing
More informationHow T cells recognize antigen: The T Cell Receptor (TCR) Identifying the TCR: Why was it so hard to do? Monoclonal antibody approach
How T cells recognize antigen: The T Cell Receptor (TCR) Identifying the TCR: Why was it so hard to do By the early 1980s, much about T cell function was known, but the receptor genes had not been identified
More informationA second type of TCR TCR: An αβ heterodimer
How s recognize antigen: The T Cell Receptor (TCR) Identifying the TCR: Why was it so hard to do By the early 1980s, much about function was known, but the receptor genes had not been identified Recall
More informationAntigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS
1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family
More informationTumor Antigen, Tumor Immunogenicity and Immunization
Society for Immunotherapy of Cancer 2012 Primer in Tumor Immunology and Biological Therapy of Cancer October 25 th, 2012, Bethesda, MD Tumor Antigen, Tumor Immunogenicity and Immunization Pedro Romero
More informationImmunotherapy on the Horizon: Adoptive Cell Therapy
Immunotherapy on the Horizon: Adoptive Cell Therapy Joseph I. Clark, MD, FACP Professor of Medicine Loyola University Chicago Stritch School of Medicine Maywood, IL June 23, 2016 Conflicts of Interest
More informationAndrea s SI Session PCB Practice Test Test 3
Practice Test Test 3 READ BEFORE STARTING PRACTICE TEST: Remember to please use this practice test as a tool to measure your knowledge, and DO NOT use it as your only tool to study for the test, since
More informationImmunological Tolerance
Immunological Tolerance Introduction Definition: Unresponsiveness to an antigen that is induced by exposure to that antigen Tolerogen = tolerogenic antigen = antigen that induces tolerance Important for
More informationACE ImmunoID. ACE ImmunoID. Precision immunogenomics. Precision Genomics for Immuno-Oncology
ACE ImmunoID ACE ImmunoID Precision immunogenomics Precision Genomics for Immuno-Oncology Personalis, Inc. A universal biomarker platform for immuno-oncology Patient response to cancer immunotherapies
More informationDeterminants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco
Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?
More informationDissecting therapy-induced T-cell responses in melanoma
Dissecting therapy-induced T-cell responses in melanoma Tumor-infiltrating lymphocyte (TIL) therapy of melanoma TIL are grown from melanoma tumors Rapid Expansion Infusion of TIL + IL-2 Patient pretreated
More informationAdoptive Cell Therapy: Treating Cancer
Adoptive Cell Therapy: Treating Cancer with Genetically Engineered T Cells Steven A. Feldman, Ph.D. Surgery Branch National Cancer Institute NCT Conference Heidelberg, Germany September 24, 2013 Three
More informationCancer Immunotherapy INTRODUCTION HUMAN TUMOR ANTIGENS. Cancer/Germ-Line Antigens
14 Cancer Immunotherapy Steven A. Rosenberg, Paul R. Robbins, Giao Phan, Steven Feldman, and James Kochenderfer INTRODUCTION Progress in understanding basic aspects of cellular immunology and tumor host
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationNuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico.
Nuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico. Andrea Anichini Human Tumors Immunobiology Unit Dept. of Experimental Oncology and Molecular Medicine Immune checkpoint
More informationSociety for Immunotherapy of Cancer (SITC)
Society for Immunotherapy of Cancer (SITC) Oncolytic Viruses and Their Application to Cancer Immunotherapy Ding Wang, MD, PhD Josephine Ford Cancer Institute Advances in Cancer Immunotherapy - Michigan
More informationClass I Ag processing. TAP= transporters associated with antigen processing Transport peptides into ER
Antigen processing Class I Ag processing TAP= transporters associated with antigen processing Transport peptides into ER Proteosome degrades cytosolic proteins Large, multi-subunit complex Degrades foreign
More informationAndrea s Final Exam Review PCB 3233 Spring Practice Final Exam
NOTE: Practice Final Exam Although I am posting the answer key for this practice exam, I want you to use this practice to gauge your knowledge, and try to figure out the right answer by yourself before
More informationDarwinian selection and Newtonian physics wrapped up in systems biology
Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid
More informationPrinciples of Adaptive Immunity
Principles of Adaptive Immunity Chapter 3 Parham Hans de Haard 17 th of May 2010 Agenda Recognition molecules of adaptive immune system Features adaptive immune system Immunoglobulins and T-cell receptors
More informationCentral tolerance. Mechanisms of Immune Tolerance. Regulation of the T cell response
Immunoregulation: A balance between activation and suppression that achieves an efficient immune response without damaging the host. Mechanisms of Immune Tolerance ACTIVATION (immunity) SUPPRESSION (tolerance)
More informationMechanisms of Immune Tolerance
Immunoregulation: A balance between activation and suppression that achieves an efficient immune response without damaging the host. ACTIVATION (immunity) SUPPRESSION (tolerance) Autoimmunity Immunodeficiency
More informationEvidence for antigen-driven TCRβ chain convergence in the tumor infiltrating T cell repertoire
Evidence for antigen-driven TCRβ chain convergence in the tumor infiltrating T cell repertoire Geoffrey M. Lowman, PhD Senior Staff Scientist EACR - 02 July 2018 For Research Use Only. Not for use in diagnostic
More informationThe Major Histocompatibility Complex (MHC)
The Major Histocompatibility Complex (MHC) An introduction to adaptive immune system before we discuss MHC B cells The main cells of adaptive immune system are: -B cells -T cells B cells: Recognize antigens
More informationSupporting Information
Supporting Information Chapuis et al. 10.1073/pnas.1113748109 SI Methods Selection of Patients, Targets, Isolation, and Expansion of Melanoma- Specific CTL Clones. Patients were HLA-typed, and their tumors
More informationMolecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy
Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,
More informationCHAPTER 9 BIOLOGY OF THE T LYMPHOCYTE
CHAPTER 9 BIOLOGY OF THE T LYMPHOCYTE Coico, R., Sunshine, G., (2009) Immunology : a short course, 6 th Ed., Wiley-Blackwell 1 CHAPTER 9 : Biology of The T Lymphocytes 1. 2. 3. 4. 5. 6. 7. Introduction
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 11 T-Cell Activation, Differentiation, and Memory Copyright 2013 by W. H. Freeman and
More informationHARNESS THE POWER OF THE IMMUNE SYSTEM TO FIGHT CANCER
OncoPept TM HARNESS THE POWER OF THE IMMUNE SYSTEM TO FIGHT CANCER OncoPept identifies and delivers priortized T-cell neo-epitopes from the patient's tumor mutanome 2 What is OncoPept? OncoPept is an integrated
More informationThe Adaptive Immune Response. T-cells
The Adaptive Immune Response T-cells T Lymphocytes T lymphocytes develop from precursors in the thymus. Mature T cells are found in the blood, where they constitute 60% to 70% of lymphocytes, and in T-cell
More informationSpontaneous. Tumour induction. Immunosuppression
Tumor immunology is the study of : 1- The antigenic properties of the tumor cells 2- The host IR to these tumor cell 3- The immunologic consequences to the host of the growth of the malignant cells 4-
More informationAntibodies and T Cell Receptor Genetics Generation of Antigen Receptor Diversity
Antibodies and T Cell Receptor Genetics 2008 Peter Burrows 4-6529 peterb@uab.edu Generation of Antigen Receptor Diversity Survival requires B and T cell receptor diversity to respond to the diversity of
More informationSupplementary Information
Supplementary Information High throughput epitope discovery reveals frequent recognition of neo-antigens by CD4 + T-cells in human melanoma Carsten Linnemann, Marit M. van Buuren, Laura Bies, Els M.E.Verdegaal,
More informationAllergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD.
Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Chapter 19: Tolerance, Autoimmunity, and Autoinflammation Prepared
More informationAdaptive Immune System
Short Course on Immunology Adaptive Immune System Bhargavi Duvvuri Ph.D IIIrd Year (Immunology) bhargavi@yorku.ca Supervisor Dr.Gillian E Wu Professor, School of Kinesiology and Health Sciences York University,
More informationCell Therapies. John HaanenMD PhD
Cell Therapies John HaanenMD PhD My disclosures I have provided consultation, attended advisory boards, and/or provided lectures for: Pfizer, Bayer, MSD, BMS, IPSEN, Novartis, Roche/Genentech, Astra Zeneca/MedImmune,
More informationT Cell Receptor Optimized Peptide Skewing of the T-Cell Repertoire Can Enhance Antigen Targeting
T Cell Receptor Optimized Peptide Skewing of the T-Cell Repertoire Can Enhance Antigen Targeting Julia Ekeruche-Makinde 1*, Mathew Clement 1*, David K Cole 1*, Emily S J Edwards 1, Kristin Ladell 1, John
More informationRational approaches to human cancer immunotherapy
Rational approaches to human cancer immunotherapy Ian D. Davis, Michael Jefford, Phillip Parente, and Jonathan Cebon Ludwig Institute for Cancer Research, Austin & Repatriation Medical Centre, Heidelberg,
More informationImmunocore Ltd isbtc Washington 30 th October 2009
Ltd isbtc Washington 30 th October 2009 Bent Jakobsen Chief Scientific Officer Breaking immune tolerance to cancer The immune system has more cytotoxic potential and versatility than can be achieved with
More informationImmuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu HSL GeneticEpi Center,
More informationDefensive mechanisms include :
Acquired Immunity Defensive mechanisms include : 1) Innate immunity (Natural or Non specific) 2) Acquired immunity (Adaptive or Specific) Cell-mediated immunity Humoral immunity Two mechanisms 1) Humoral
More informationSelf Tolerance and MHC Restriction. Dr. Issa Abu-Dayyeh
Self Tolerance and MHC Restriction Dr. Issa Abu-Dayyeh How do we teach B and T cells not to recognise self antigens as dangerous? How do we restrict T cells to recognise only Ags presented on a self MHC
More informationAttribution: University of Michigan Medical School, Department of Microbiology and Immunology
Attribution: University of Michigan Medical School, Department of Microbiology and Immunology License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution
More informationImmunotherapy: The Newest Treatment Route
Immunotherapy: The Newest Treatment Route IWMF Patient Forum, Phoenix, AZ Madhav Dhodapkar, MD Professor of Medicine and Immunobiology Chief, Section of Hematology Yale University or the Oldest William
More information- Defined as approaches that enhance, suppress or modify the immune system to treat or cure diseases.
암의면역치료 권병세 Immunotheraphy - Defined as approaches that enhance, suppress or modify the immune system to treat or cure diseases. - Applied for the treatment of cancer, autoimmune diseases, transplant rejection,
More informationForeign antigens in human cancers
Foreign antigens in human cancers Lorenzo Fanchi PhD student, Ton Schumacher Lab ESMO Preceptorship on Immuno-Oncology May 26th, 2017 IMMUNE CHECKPOINT INHIBITION SHOWS CLINICAL BENEFIT IN DIFFERENT TUMOR
More informationFollicular Lymphoma. ced3 APOPTOSIS. *In the nematode Caenorhabditis elegans 131 of the organism's 1031 cells die during development.
Harvard-MIT Division of Health Sciences and Technology HST.176: Cellular and Molecular Immunology Course Director: Dr. Shiv Pillai Follicular Lymphoma 1. Characterized by t(14:18) translocation 2. Ig heavy
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/39812 holds various files of this Leiden University dissertation Author: Buuren, Marit M. van Title: Analysis of the neo-antigen specific T cell response
More informationAntigen Recognition by T cells
Antigen Recognition by T cells TCR only recognize foreign Ags displayed on cell surface These Ags can derive from pathogens, which replicate within cells or from pathogens or their products that cells
More information5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x)
Immune surveillance 5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x) Transplanted patients following an immunosuppressor therapy are 80 times more likely to develop
More informationFocus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human melanoma
Cancer Immun 1424-9634Academy of Cancer Immunology Cancer Immunity (2 April 2009) Vol. 9, p. 3 Copyright 2009 by Martin C. Mihm Jr. 090101 Review Focus on TILs: Prognostic significance of tumor infiltrating
More informationExploring Therapeutic Combinations with anti-ctla-4 Antibody
Exploring Therapeutic Combinations with anti-ctla-4 Antibody Padmanee Sharma, MD, PhD Associate Professor GU Medical Oncology and Immunology M. D. Anderson Cancer Center isbtc Hot Topic Symposium October
More informationTumor Microenvironment and Immune Suppression
Tumor Microenvironment and Immune Suppression Hassane M. Zarour,, MD Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute Hallmarks of Cancer: The Next Generation
More informationPotential cross reactions between HIV 1 specific T cells and the microbiome. Andrew McMichael Suzanne Campion
Potential cross reactions between HIV 1 specific T cells and the microbiome Andrew McMichael Suzanne Campion Role of the Microbiome? T cell (and B cell) immune responses to HIV and Vaccines are influenced
More informationLESSON 2: THE ADAPTIVE IMMUNITY
Introduction to immunology. LESSON 2: THE ADAPTIVE IMMUNITY Today we will get to know: The adaptive immunity T- and B-cells Antigens and their recognition How T-cells work 1 The adaptive immunity Unlike
More informationNIH Public Access Author Manuscript Science. Author manuscript; available in PMC 2008 March 12.
NIH Public Access Author Manuscript Published in final edited form as: Science. 2006 October 6; 314(5796): 126 129. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes Richard
More informationSupplementary Table 1. Functional avidities of survivin-specific T-cell clones against LML-peptide
Supplementary Table 1. Functional avidities of survivin-specific T-cell clones against LML-peptide pulsed T2 cells. clone avidity by 4-hour 51 Cr-release assay 50% lysis at E:T 10:1 [LML peptide, M] #24
More informationImmuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu Director & Associate
More informationall of the above the ability to impart long term memory adaptive immunity all of the above bone marrow none of the above
1. (3 points) Immediately after a pathogen enters the body, it faces the cells and soluble proteins of the innate immune system. Which of the following are characteristics of innate immunity? a. inflammation
More informationCurrent practice, needs and future directions in immuno-oncology research testing
Current practice, needs and future directions in immuno-oncology research testing Jose Carlos Machado IPATIMUP - Porto, Portugal ESMO 2017- THERMO FISHER SCIENTIFIC SYMPOSIUM Immune Therapies are Revolutionizing
More informationA Multifaceted Immunomonitoring to Identify Predictive Biomarkers for the Clinical Outcome of Immunotherapy-Treated Melanoma Patients
A Multifaceted Immunomonitoring to Identify Predictive Biomarkers for the Clinical Outcome of Immunotherapy-Treated Melanoma Patients Immunotherapy Biomarkers: Overcoming the Barriers NIH, Bethesda, April
More informationAntigen-Independent B-Cell Development Bone Marrow
Antigen-Independent B-Cell Development Bone Marrow 1. DNA rearrangements establish the primary repertoire, creating diversity 2. Allelic exclusion ensures that each clone expresses a single antibody on
More informationImmunotherapy Using T Cell Defined Tumor Antigens for Melanoma
Microbiol. Immunol., 42(12), 803-813, 1998 Minireview Immunotherapy Using T Cell Defined Tumor Antigens for Melanoma Yutaka Kawakami Division of Cellular Signaling, Institute for Advanced Medical Research,
More informationCurrent Tumor Immunotherapy
Current Tumor Immunotherapy Part 1: On the preclinical and clinical efficacy of the current cancer vaccines. Part 2: The critical role of cancer vaccines in new integrative approaches. The State of the
More informationT cell maturation. T-cell Maturation. What allows T cell maturation?
T-cell Maturation What allows T cell maturation? Direct contact with thymic epithelial cells Influence of thymic hormones Growth factors (cytokines, CSF) T cell maturation T cell progenitor DN DP SP 2ry
More informationThe functional investigation of the interaction between TATA-associated factor 3 (TAF3) and p53 protein
THESIS BOOK The functional investigation of the interaction between TATA-associated factor 3 (TAF3) and p53 protein Orsolya Buzás-Bereczki Supervisors: Dr. Éva Bálint Dr. Imre Miklós Boros University of
More informationκ λ Antigen-Independent B-Cell Development Bone Marrow Ordered Rearrangement of Ig Genes During B-Cell Development in the Bone Marrow
Antigen-Independent B-Cell Development Bone Marrow 1. DNA rearrangements establish the primary repertoire, creating diversity 2. Allelic exclusion ensures that each clone expresses a single antibody on
More informationAdoptive T Cell Therapy:
Adoptive T Cell Therapy: A Paradigm for Combination Strategies Cassian Yee MD Professor Melanoma Medical Oncology Immunology Director Solid Tumor Cell Therapy cyee@mdanderson.org skype name: tcelltherapy
More informationImmune surveillance hypothesis (Macfarlane Burnet, 1950s)
TUMOR-IMMUNITÄT A.K. Abbas, A.H. Lichtman, S. Pillai (6th edition, 2007) Cellular and Molecular Immunology Saunders Elsevier Chapter 17, immunity to tumors Immune surveillance hypothesis (Macfarlane Burnet,
More informationAutoimmune diseases. Autoimmune diseases. Autoantibodies. Autoimmune diseases relatively common
Autoimmune diseases Fundamental abnormality: the adaptive immune system is triggered by self antigens to initiate a sustained immune response against self molecules that results in tissue injury Specificity
More informationImmune Tolerance. Kyeong Cheon Jung. Department of Pathology Seoul National University College of Medicine
Immune Tolerance Kyeong Cheon Jung Department of Pathology Seoul National University College of Medicine Immune tolerance Unresponsiveness to an antigen that is induced by previous exposure to that antigen
More informationImmunology for the Rheumatologist
Immunology for the Rheumatologist Rheumatologists frequently deal with the immune system gone awry, rarely studying normal immunology. This program is an overview and discussion of the function of the
More information